The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks Dafad for that.
I found Michel Goldmans closing comments very interesting. Convalescent plasma being difficult to organise but maybe suitable for developing countries only. Surprised they are still discussing this after initial negative test results. The alternative mcabs have two drawbacks , namely production capacity and cost. The elephant in the room was that the interviewer did not want Goldman to expand on the inhaled interferon treatment he mentioned, it sounded very like he was specifically talking about Synairgen, despite the fact that it ticks all the boxes, depending on price perhaps, for early treatment . It seemed clear that most of the doctors were agreed that a treatment to prevent ventilation was what is desperately needed.
Also, the other very interesting point made by Goldman was that we urgently need research , perhaps using AI to determine people who are likely to progress to serious disease for whatever reason. This is because whatever treatments we find , even probably SNG001, are unlikely to be able to be utilised for a significant proportion of people who test positive. The available early stage treatments being expensive and rare at present need to be targeted to those who will most benefit. I read today that there are a number of blood markers that are indicative of infection without antigen test and some of these markers are able to inform likely severity of disease and mortality.
On this latter point I imagine it will be a year or two before that is organised and without this Synairgen's inhaled treatment is most definitely the number one likely useful candidate at present.
Despite SP reduction today everyone should be feeling positive and I am really quite excited about the progression of our journey in the next two to three months.
Spinnaker
"Less than 20 patients to go, which in the peak of the pandemic would be two days. Now it's probably going to be two weeks".
Different trial, but, hopefully, gives us an idea about recruitment rates. At 10 patients a day we'll fill our UK arm pretty quickly. Not sure how many hospitals are now recruiting though - RM really needs to do a big positive interview.
Excellent find Dafad, 4.20mins on the button, Synairgen. THanks
Hold4resusults funnily enough I was looking at this detail last night. I think there maybe a trial in care homes. It is very similar to how Elli lily did a trial in us care homes to. That is the perfect setting with given age related. I’ll do some more digging out of the documents I had last night.
Don't hold me to it but IIRC Holgate's comment was actually sparked by a poster here asking about the possibility of prophylactic use. Obviously SNG001 will not help with long term protection if the patient does not get covid, but if you have an outbreak in a confined environment like a care home, you might want to boost everyone's immune system for a few weeks.
Holgate casually mentioned use in care homes in a video months ago.
If it happens it will be this trial: https://www.nihr.ac.uk/news/new-trial-to-test-drugs-for-preventing-covid-19-in-care-homes/26684
It's not a million miles away from the Activ2 platform setup - large number of sites, up to 3 drugs on trial at once etc.
Dafad, another great find, you are not related to pmjh by any chance?
4 trials? They don't call him Richard Data is King Marsden for nothing!
Fairly daming statement ... nothing to suprise us but seeing it in a write up of a gov sponsored trial is powerful ...
"the effectiveness of vaccines in this group has not yet been fully established"
https://www.nottingham.ac.uk/news/protect
Could SNG be involved with this?
Thanks Dafad. It's clear SNG001 is now on everyone's radar. Now just need positive data.
The guy who mentions inhaled interferon has some pedigree
https://en.wikipedia.org/wiki/Michel_Goldman
Watch from 4min 20 sec
https://www.youtube.com/watch?v=g9JM7i5aCE8